Abstract:Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a widely used drug for anesthesia. However, increasing studies have focused on the potential antidepressant effects of ketamine. As mentioned in the review of Szewczyk et al. [1], subunit selective NMDA receptor antagonists exert the same antidepressant efficacy of ketamine but with fewer adverse effects. Indeed, the authors make a good comment and indicate a bright research future of developing novel antidepressants. However, we cannot neglect another vital receptor modulator a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor agonist. Compared with conventional antidepressants, the most eye-catching superiority of NMDA receptor antagonists is their fast-acting and robust therapeutic effects for depression and even for treatment-resistant depression [2]. However, with regard to AMPA agonists, large previous studies have shown that they also exert exact antidepressant effects with a rapid onset time [3]. Moreover, mounting evidences indicate that ketamine-elicited antidepressant effects require the activation of AMPA receptors [4,5]. And until now, the researches on antidepressant action of AMPA agonists are not enough and there is no study reporting the severe side effects of AMPA agonists. In conclusion, further researches on AMPA receptor agonists for depression treatment will bring us a bright future for developing novel antidepressants.

A Bright Future of Researching AMPA Receptor Agonists for Depression Treatment